Summary
Cardiovascular disease has become the major cause of death in the Western countries. There is strong evidence that elevations of serum lipids contribute to the pathogenesis of premature atherosclerosis. The classification of the hyperlipoproteinemias has been most beneficial as a guide to development of dietary and pharmacological regimens for lowering serum lipid concentrations. The results of dietary and drug prevention trials are discussed. Insight into the mechanisms involved in lipoprotein metabolism as well as the mode of action and of side-effects of hypolipidemic drugs is reviewed. Using present knowledge of heart disease research, it is reasonable to suggest dietary and drug treatments for the high risk patient.
Zusammenfassung
Cardiovasculäre Erkrankungen sind die Haupttodesursache in den westlichen Ländern. Es ist erwiesen, daß Erhöhungen der Serumlipide zur frühzeitigen Entstehung der Arteriosklerose beitragen. Mit der Klassifikation der Hyperlipoproteinämien entstand die Grundlage für gezielte diätetische und pharmakologische Behandlungskonzepte zur Senkung der Serumlipidkonzentrationen. Es werden die Ergebnisse medikamentöser und diätetischer Präventivstudien diskutiert und die Erkenntnisse über den Stoffwechsel der Lipoproteine sowie Wirkungsweise und Nebenwirkungen der gebräuchlichsten lipidsenkenden Medikamente dargestellt. Es ist zum gegenwärtigen Zeitpunkt berechtigt, Patienten mit besonderer Disposition zur frühzeitigen Arteriosklerose diätetisch und medikamentös zu behandeln.
Similar content being viewed by others
Literatur
Rider. A.K.: Should hyperlipoproteinemia be treated in patients with coronary heart disease. JAMA233, 275–277 (1975)
Ahrens, E.H., Jr.: The management of hyperlipidemia: whether, rather than how. Ann. Int. Med.85, 87–93 (1976)
Miettinen, M., Turpeinen, O., Karvonen, M.J. et al.: Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. Lancet2, 835–838 (1972)
Turpeinen, O., Miettinen, M., Karvonen, M.J. et al.: Dietary prevention of coronary heart disease. Amer. J. Clin. Nutr.21, 255–276 (1968)
Oliver, M.F.: Ischaemic heart disease: a secondary prevention trial using clofibrate. Brit. Med. J.4, 775–784 (1971)
Dewar, H.A.: Trial of clofibrate in the treatment of ischaemic heart disease. Brit. Med. J.4, 767–775 (1971)
Krasno, L.R., Kidera, G.J.: Clofibrate in coronary heart disease: effect on morbidity and mortality. JAMA219, 845 (1972)
Stamler, J.: The Coronary Drug Project. JAMA231, 360–381 (1975)
Kannel, W.B., Castelli, W.P., Gordon, T., McNamara, P.M.: Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Int. Med.55, 33–50 (1961)
Truett, J., Cornfield, J., Kannel, W.B.: Multivariate analysis of risk of coronary heart disease in Framingham. J. Chronic Dis.20, 511–524 (1967)
Kannel. W.B., Castelli, W.P., Gordon, T.: Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Int. Med.74, 1–12 (1971)
Patterson, D., Slack, J.: Lipid abnormalities in male and female survivors of myocardial infarction and their first degree relatives. Lancet1, 393–399 (1972)
Epstein, F.H., Ostrander, L.D.: Detection of individual susceptibility toward coronary artery disease. Progr. Cardiovasc. Dis.13, 324–342 (1971)
Goldstein, J.L., Hazzard, W.R., Schrott, H.G.: Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J. clin. Invest.52, 1533–1543 (1973)
D.S. Fredrickson, R.I. Levy: Familial hyperlipoproteinemia. In: The Metabolic Basis of Inherited Disease. J.B. Stanbury, J.B. Wyngaarden, D.S. Fredrickson (eds.), McGraw-Hill, New York 1972, 545
Anitschkow, N.: Über die Veränderung der Kaninchenaorta bei experimenteller Cholesterinsteatose. Beitr. Path. Anat.56, 379–404 (1913)
Wissler, R., Eilert, M.C., Schroeder, M.A., Cohen, L.: Production of lipomatous and atheromatous arterial lesions in the albino rat. Arch. Path.57, 333–351 (1954)
Kritchevsky, D.: Experimental atherosclerosis. In: Lipid Pharmacology. R. Paoletti (ed.), Academic Press Inc., New York 1964, 63–130
Ross, R., Harker, L.: Hyperlipidemia and atherosclerosis. Science193, 1094 (1976)
Bencze, W.L., Hess, R., Destevens, G.: Hypolipidemic agents. In: Progress Drug Res. Jucker, E. (ed.), Birkhaeuser, Basel 1969, 13, 217
Fredrickson, D.S., Levy, R.I., Lees, R.S.: Fat transport. An integrated approach to mechanisms and disorders. New Engl. J. Med.276, 32–44, 94–103, 148–156, 215–226, 273–281 (1967)
Greten, H.: Klinik und Klassifizierung primärer Hyperlipoproteinämien. In: Fettstoffwechselstörungen, ihre Erkennung und Behandlung. G. Schettler (ed.), Thieme-Verlag, Stuttgart 1971, 4
Seidel, D.: Plasmalipoproteine — Funktion und Charakterisierung. In: Fettstoffwechselstörungen, ihre Erkennung und Behandlung. G. Schettler (ed.), Thieme-Verlag, Stuttgart 1971, 24
Morrisett, J.D., Jackson, R.L., Gotto, A.M.: Lipoproteins — structure and function. Ann. Rev. Biochem.44, 183 (1975)
Middelhoff, G., Augustin, J., Klose, G., Greten, H.: Lipid-Protein-Wechselwirkungen menschlicher Apolipoproteine — Entwicklung von Lipoproteinmodellen. Klin. Wschr.55, 149 (1977)
Levy, R.I., Blum, C.B., Schaefer, E.J.: The composition, structure and metabolism of high density lipoprotein. In: Lipoprotein Metabolism. H. Greten (ed.), Springer-Verlag Berlin Heidelberg New York 1976, 56
Miller, G.J., Miller, N.E.: Plasma-high-density-lipoprotein concentration and development of ischemic heart disease. Lancet4, 16 (1975)
Stein, O., Stein, Y.: Comparative uptake of rat and human serum low-density and high-density lipoproteins by rat aortic smooth muscle cells in culture. Circulat. Res.36, 436 (1975)
Greten, H.: Lipoprotein Metabolism. Springer-Verlag Berlin Heidelberg New York 1976
Eisenberg, S.: Lipoprotein metabolism and hyperlipidemia. In: Atherosclerosis Reviews. R. Paoletti, A.M. Gotto (eds.), Raven Press, New York 1976, 23
Augustin, J., Middelhoff, G., Brown, W.V.: Metabolismus der Lipoproteine. In: Handbuch der Inneren Medizin, Band VII/4. G. Schettler, H. Greten, G. Schlierf, D. Seidel (eds.), Springer-Verlag Berlin Heidelberg New York 1976, 219
Havel, J.R.: Mechanisms of hyperlipoproteinemia. Arch. Exp. Biol. Med.26, 57 (1972)
Greten, H.: Untersuchungen zum Stoffwechsel menschlicher Chylomikronen. Klin. Wschr.52, 947 (1974)
Goldstein, J.L., Brown, M.S.: Familial hypercholesterolemia: a genetic regulatory defect in cholesterol metabolism. Amer. J. Med.58, 147 (1975)
Bergen, S.S., Jr., van Itallie, T.B., Tenneat, D.M., Sebrell, W.H.: Effect of anion exchange resin on serum cholesterol in man. Proc. Soc. Exp. Biol.102, 676 (1959)
Carey, J.B.: Lowering of serum bile acid concentration and relief of pruritus of jaundiced patients fed a bile acid sequestering resin. J. Lab. Clin. Med.36, 797 (1960)
Bergen, S.S., Jr., van Itallie, T.B.: Approaches to the treatment of hypercholesterolemia. Ann. Intern. Med.38, 355 (1963)
Parkinson, T.M.: Hypolipidemic effects of orally administered dextran and cellulose anion exchanges on cockerels and dogs. J. Lipid Res.8, 24 (1967)
Howard, A.N., Hyanes, D.E.: Combined use of clofibrate and cholestyramine or DEAE-Sephadex in hypercholesterolaemia. Brit. Med. J.3, 25 (1971)
Nye, E.R., Jackson, D., Hunter, J.D.: Treatment of hypercholesterolaemia with colestipol, a bile sequestering agent. New Zeal. N.Z. Med.22, 235 (1971)
Parkinson, T.M., Gundersen, K., Nelson, N.A.: Effect of colestipol (U-26, 597 A), a new bile acid sequestrant on serum lipids in experimental animals and man. Atherosclerosis II, 531 (1970)
Glueck, C.J., Ford, S., Scheel, D., Steiner, P.: Colestipol and cholestyramine resin. J. Amer. Med. Ass.222, 676 (1972)
Carey, J.B., Jr., Williams, G.: Relief of pruritus of jaundice with a bile-acid sequestering resin. J. Amer. Med. Ass.176, 432 (1961)
Miettinen, T.A.: Drugs affecting bile acid and cholesterol excretion. In: Atherosclerosis, Proc. 2nd Int. Symp., R.J. Jones (ed.), Springer-Verlag Berlin Heidelberg New York 1970, 508
Moore, R.B., Crane, C.A., Frantz, I.D., Jr.: Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient. J. clin. Invest.47, 1664 (1968)
Grundy, S.M., Ahrens, E.H., Jr., Salen, G.: Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. clin. Med.78, 94 (1971)
Howard, R.P., Brusco, O.J., Furman, R.H.: Effect of cholestyramine administration on serum lipids and on nitrogen balance in familial hypercholesterolemia. J. Lab. clin. Med.68, 12 (1966)
Lees, A.M., McCluskey, M.A., Lees, R.S.: Results of colestipol therapy in Type II hyperlipoproteinemia. Atherosclerosis24, 129 (1976)
Gustafson, A., Langer, A.: Treatment of HLP Type II a with a new anion exchange resin secholex. Europ. J. clin. Pharmacol.7, 65 (1974)
Howard, A.N., Courtenay, E.R.J.: Secholex, clofibrate and taurine in hyperlipidemia. Atherosclerosis20, 105 (1974)
Ritland, S., Fausa, O., Gjone, E., Blomhoff, J.P., Skrede, S., Lanner, A.: Effect of treatment with a bile sequestering agent (Secholex®) on intestinal absorption, duodenal bile acids and plasma lipids. Scand. J. Gastroent.10, 791 (1975)
Nikkilä, E.A., Miettinen, T.A., Lanner, A.: Treatment of hypercholesterolemia with secholex. A long-term clinical trial and comparison with cholestyramine. Atherosclerosis24, 407 (1976)
Levy, R.I., Fredrickson, D.S., Stone, N.J. et al.: Cholestyramine in Type II hyperlipoproteinemia — a double blind trial. Ann. Int. Med.79, 51 (1973)
Thompson, G.R., Mac Mahon, M., Claes, P.: Precipitation by neomycin compounds of fatty acid and cholesterol from mixed micellar solutions. Europ. J. clin. Invest.1, 40 (1970)
Grundy, S.M., Ahrens, E.H., Jr.: Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods. J. Lipid Res.10, 91 (1969)
Lees, R.S., Lees, A.M.: Effects of sitosterol therapy on plasma lipid and lipoprotein concentrations. In: Lipoprotein Metabolism, H. Greten (ed.). Springer-Verlag Berlin Heidelberg New York 1976, 119
Oster, P., Schlierf, G., Heuck, C.C. et al.: Sitosterin bei familiärer Hyperlipoproteinämie Typ II. Dtsch. Med. Wschr.101, 1308 (1976)
Boyd, G.S., Oliver, M.F.: Effect of certain thyroxine analogues on the serum lipids in human subjects. J. Endocr.21, 33 (1960)
Oliver, M.F., Boyd, G.S.: Reduction of serum cholesterol by dextrothyroxine in men with coronary heart disease. Lancet1, 783 (1961)
Strisower, B., Gofman, J.W., Rubin, L., Rosenthal, D., De Lalla, O.: The effect of desiccated thyroid on the hyperlipoproteinemia of xanthoma tendinosum. Amer. J. Med. Sci.239, 71 (1960)
Rosenman, R.H., Byers, S.O., Frialman, M.: Mechanisms responsible for altered blood cholesterol content in deranged thyroid states. J. clin. Endocrin.12, 1287 (1952)
Kritchevsky, D.: Influence of thyroid hormones and related compounds on cholesterol biosynthesis and degradation. Metabolism9, 984 (1960)
Rabinowitz, J.L., Rodman, T., Myerson, R.M.: Effect of dextrothyroxine on metabolism of C14-labeled cholesterol and tripalmitin. JAMA 118 (1963)
Simons, L.A., Myant, N.B.: The effect of D-thyroxine on the metabolism of cholesterol in familial hyperbetalipoproteinemia. Atherosclerosis19, 103 (1974)
Miéttinen, T.A.: Mechanism of serum cholesterol reduction by thyroid hormones in hypothyroidism. J. Lab. clin. Med.71, 537 (1968)
Nikkilä, E.A., Kekki, M.: Plasma triglyceride metabolism in thyroid disease. J. clin. Invest.51, 2103 (1972)
Scheiffele, E., Schultze, K.W.: Letters to the editor. JAMA8, 221 (1972)
Klemens, U.H., v. Löwis of Menar, P.: Behandlung primärer Hyperlipoproteinämien vom Typ II a, II b mit hochgereinigtem D-Thyroxin. Dtsch. Med. Wschr.99, 487 (1974)
Bommer, J., Speders, H., Ehrke, V.: Behandlung der Hypercholesterinämie nach Herzinfarkt mit D-Thyroxin. Münch. Med. Wschr.4, 139 (1975)
Koschinsky, T., Vogelberg, K.H., Gries, F.A.: Therapie primärer Hyperlipoproteinämie II a und II b mit D-Thyroxin. Dtsch. Med. Wschr.11, 494 (1974)
Rakow, A.D., Ditschuneit, H.H., Küter, E., Ditschuneit, H.: Der Einfluß von D-Thyroxin-Na (Dynothel) auf die Hypercholesterinämie. Verh. Dtsch. Ges. Inn. Med.80, 1259 (1974)
Rakow, A.D., Klör, H.U., Küter, E., Ditschuneit, H.H., Ditschuneit, H.: Treatment of Type II hyperlipoproteinemia with D-Thyroxine. Atherosclerosis24, 369 (1976)
Schwartzkopff, W., Russ, E.: Langzeit-Therapie von Hyperlipoproteinämien der Typen II a, II b mit Etiroxat. Dtsch. Med. Wschr.100, 815 (1975)
Altschul, R., Hoffer, A., Stephen, J.D.: Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys.54, 558 (1955)
Parsons, W.B., Jr.: Chemotherapy of hyperlipidemia. Mayo Clin. Proc.40, 822 (1965)
Carlson, L.A., Okö, J., Ostman, J.: Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment. J. Atheroscler. Res.8, 667 (1968)
Parsons, W.B., Jr.: Treatment of hypercholesterolemia by nicotinic acid: progress report with a review of studies regarding mechanism of action. Arch. Int. Med.107, 639 (1961)
Gey, K.F., Carlson, L.A.: Metabolic effects of nicotinic acid and its derivatives. Hans Huber Verlag, Bern 1971
Langer, T., Levy, R.I.: Effect of nicotinic acid on beta lipoprotein metabolism (Abstr.). Clin. Res.18, 458 (1970)
Magide, A.A., Myant, N.B.: Effect of nicotinic acid on cholesterol metabolism in monkeys. Clin. Sci. Molec. Med.46, 527 (1972)
Magide, A.A., Myant, N.B., Reichl, D.: The effect of nicotinic acid on the metabolism of the plasma lipoproteins of rhesus monkeys. Atherosclerosis21, 205 (1975)
Carlson, L.A.: Inhibition of the mobilization of free fatty acids from adipose tissue. Ann. N.Y. Acad. Sci.131, 119 (1965)
Miettinen, T.A.: Methods for evaluation of hypolipidemic drugs in man: mechanisms of their action. In: Lipid Pharmacology, Vol. II, R. Paoletti and C.J. Glueck (eds.). Academic Press, New York 1976, 83
Miettinen, T.A.: Effect of nicotinic acid on catabolism and synthesis of cholesterol in man. Clin. Chim. Acta20, 43 (1968)
Zöllner, N., Gudensi, M.: Behandlung der Hypercholesterinämie mit Beta-Pyridylcarbinol. I. Biochemie und klinische Ergebnisse. Med. Klin.61, 1996 (1966)
Nelemans, F.A.: Report on a double-blind investigation into the influence of β-pyridylcarbinol on the cholesterol level of the blood. Arzneimittel-Forsch. (Drug Res.)22, 1410 (1972)
Carlson, L.A., Oro, L.: Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis18, 1 (1973)
Thorp, J.M., Warnnig, W.S.: Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature194, 948 (1962)
Rueghamer, W.R., Ryan, N.T., Richert, D.A., Westerfeld, W.W.: The effects of p-chlorophenoxyisobutyrate on the turnover rate and distribution of thyroid hormone in the rat. Biochem. Pharmacol.19, 613 (1969)
Cheng, C.Y., Feldman, E.B.: Clofibrate, inhibitor of intestinal cholesterogenesis. Biochem. Pharmacol.20, 3509 (1971)
White, L.W.: Regulation of hepatic cholesterol biosynthesis by clofibrate administration. J. Pharmacol. Exp. Theo.178, 361 (1971)
Adams, L.L., Webb, W.W., Fallon, H.J.: Inhibition of hepatic triglyceride formation by clofibrate. J. clin. Invest.50, 2339 (1971)
Duncan, C.H., Best, M.M.: Inhibition of hepatic secretion of triglycerides by chlorophenoxyisobutyrate (CPIB). Circulation30, 111 (1964)
Gould, R.G., Swyryd, E.H., Coan, B.J. et al.: Effects of chlorophenoxyisobutyrate (CPIB) on liver composition and triglyceride synthesis in rats. J. Atheroscler. Res.6, 555 (1966)
Rifkind, B.M.: Effect of CPIB ester on plasma free fatty acid levels in man. Metabolism15, 673 (1966)
Grundy, S.M., Ahrens, E.H., Jr., Salen, G.: Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J. Lipids Res.13, 531 (1972)
Kather, H., Simon-Crisan, G., Simon, B.: Inhibition of human fat cell adenylate cyclase by clofibrate. Horm. Metabol. Res.8, 146 (1976)
Schettler, G., Mordasini, R., Zipperle, G., Klar, E., Laible, V., Greten, H.: Der Wirkungsmechanismus synthetischer Heparinoide — Resultate bei Patienten mit Hypertriglyceridämie. Dtsch. Med. Wschr., in press (1977)
Beaumont, J.L., Bachet, C.: Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters. Its significance for the mechanism of lipid lowering by clofibrate and related drugs. Atherosclerosis25, 255 (1976)
Langer, T., Levy, R.I.: Acute muscular syndrome associated with administration of clofibrate. New Engl. J. Med.279, 856 (1968)
Thistle, J.L., Schoenfield, L.J.: Induced alterations in composition of bile of persons having cholelithiasis. Gastroenterology61, 488 (1971)
Summerfield, J.A., Elias, E., Sherlock, S.: Effects of clofibrate in primary biliary cirrhosis, hypercholesterolemia and gallstones. Gastroenterology69, 993 (1975)
Levy, R.I., Quarfordt, S.H., Brown, W.V. et al.: The efficacy of clofibrate (CPIB) in familial hyperlipoproteinemias. In: Drugs Affecting Lipid Metabolism, W.L. Holmes, L.A. Carlson, R. Paoletti (eds.), Proceedings. Plenum Press, New York 1969, 377
Schlierf, G., Kahlke, W., Reinheimer, W.: Langzeitbehandlung primärer Hyperlipidämien mit Clofibrat. Fortschritte Med.88, 907 (1970)
Hellman, L., Zumoff, B., Kessler, G. et al.: Reduction of cholesterol and lipids in man by ethyl-p-chlorophenoxyisobutyrate. Ann. Int. Med.59, 477 (1963)
Oliver, M.F.: Further observations on the effects of atromid and of ethyl chlorophenoxybutyrate on serum lipid levels. J. Atheroscler. Res.3, 427 (1963)
Alaupovic, R.P., Brusco, O.J., Furman, R.H.: Effects of ethyl chlorophenoxyisobutyrate, alone or with androsterone (Atromid) on serum lipids, lipoproteins and related metabolic parameters in normal and hyperlipidemic subjects. J. Atheroscler. Res.3, 482 (1963)
Best, M.M., Duncan, C.H.: Reduction of serum triglycerides and cholesterol by ethyl-p-chlorophenoxyisobutyrate (CPIB). Amer. J. Cardiol.15, 230 (1965)
Howard, R.P. et al.: Effects of ethyl chlorophenoxyisobutyrate alone or with androsterone (Atromid) on serum lipids, lipoproteins and related metabolic parameters in normal and hyperlipemic subjects. J. Atheroscler. Res.3, 482 (1963)
von Löwis of Menar, P., Klemens, U.H.: Behandlung primärer Hyperlipoproteinämien II a, II b, III und IV mit Clofibrat. Dtsch. Med. Wschr.98, 2328 (1973)
Schwartzkopf, W., Hoffmann, H., Kaestner, W.: Vergleichende Untersuchung zur Lipidsenkung durch Clofibrinsäure und Clofibrat bei Hyperlipoproteinämien. Med. Welt26, 2308 (1975)
Wolfram, G., Keller, C., Kilami, S., Zollmar: First clinical experiences in therapy of hyperuricemia and hyperlipidemia. Verh. Dtsch. Ges. Inn. Med.79, 2191 (1973)
Rees, E.D., Hamilton, R.D., Kanner, I.F. et al.: Halofenate in the treatment of Type II hyperlipoproteinemia. Double blind comparison with clofibrate. Atherosclerosis24, 537
Navarette, V.N., Torres, H.J., Lee, D.B., Soria, J.: Treatment with phenformin of hypercholesterolemia and hypertriglyceridemia in non diabetic subjects. Excerpta Med. Int. Congr. Ser.140, 45 (1967)
Stout, R.W., Brunzell, J.D., Porte, D., Bierman, L.E.: Effect of phenformin on lipid transport in hypertriglyceridemia. Metabolism9, 815 (1974)
Lang, P.D., Vollmar, J., Klemens, U.H. et al.: Die lipidsenkende Wirkung von Phenformin bei primärer Hyperlipoproteinämie Typ IV. Dtsch. Med. Wschr.48, 2280 (1973)
Vogelberg, K.H.: Die Kombination von Clofibrat und Phenformin in der Behandlung endogener Hypertriglyceridämien. Dtsch. Med. Wschr.101, 1868 (1976)
Blaton, V., Peeters, H.: Effect of unsaturated phosphatidylcholine on the lipoprotein lipase activity in vitro. In: Atherosclerosis III, G. Schettler, A. Weizel (eds.). Springer-Verlag Berlin Heidelberg New York 1974, 565
Ditschuneit, H., Klör, H.-U., Ditschuneit, H.H.: Effects of essential phospholipids on the carbohydrate-induced hypertriglyceridemia. In: Phosphatidylcholine, H. Peeters (ed.), Springer-Verlag Berlin Heidelberg New York 1976, 98
Blaton, V., Declercq, B., Vandamme, D., Soetewey, F., Peeters, H.: The human plasma lipids and lipoproteins under influence of EPL-therapy. In: Phosphatidylcholine, H. Peeters (ed.), Springer-Verlag Berlin Heidelberg New York 1976, 125
Peeters, H., Blaton, V., Soetewey, F., Declercq, B., Vandamme, D.: Wirkung der „essentiellen“ Phospholipide auf Plasmalipide und Fettsäuren bei Typ II Hyperlipoproteinämie. Münch. Med. Wschr.31, 1358 (1973)
Howard, A.N., Patelski, J., Bowyer, D.E., Gresham, G.A.: Phospholipids in experimental atherosclerosis. In: Phospholipids. Thieme-Verlag Stuttgart 1972, 79
Marmorston, J., Moore, F.J., Hopkins, C.E., Kuzma, O.T., Weiner, J.: Clinical studies of long term estrogen therapy in men with myocardial infarction. Proc. Soc. Exp. Biol.110, 400 (1962)
Glueck, C.J., Scheel, D., Fishback, J., Steiner, P.: Progestagens, anabolic-androgenic compounds, estrogens: effects on triglycerides and postheparin lipolytic enzymes. Lipids7, 110 (1972)
Best, M.M., Duncan, C.H.: Effects of clofibrate and dextrothyroxine singly and in combination on serum lipids. Arch. Intern. Med.118, 97 (1966)
Courtenay Evans, R.J., Howard, A.N., Hyams, D.E.: An effective treatment of hypercholesterolaemia using a combination of secholex and clofibrate. Angiology24, 22 (1973)
Fellin, R., Baggio, G., Balestrieri, P.: Les effets du colestipol associé au clofibrate sur les lipides seriques dans l'hyperlipoproteinemie familiale du Type II. Rev. Franc. Endocrin. Clin.15, 445 (1974)
De Witt S. Grotman, Noble, R.P., Bell, R.B.: The effect of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man. J. clin. Invest.52, 2646 (1974)
Stein, E.A., Heimann, K.W.: Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperlipoproteinemia. South Afr. Med. J.49, 1252 (1975)
Färgeman, O.: Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin. Acta Med. Scand.194, 165 (1973)
Knüchel, F.: Wirkung eines neuen lipidsenkenden Medikamentes (Etofibrat) bei Hyperlipoproteinämie Typ II. Med. Welt25, 1766 (1974)
Mann, S., Maisenbacher, H.-J.: Klinische Prüfung einer Kombination von Clofibrat und β-Pyridylcarbinol mit ungewöhnlicher Dosisrelation. Zeitschr. f. Allgemeinmed.24, 1066 (1975)
Leopold, G., Simane, Z., Stole, K.D., Breuer, J.: Vergleichende klinisch-pharmakologische Untersuchung der lipidsenkenden Wirkung von EMO 100 und Clofibrat. Med. Welt26 (N.F.), 1542 (1975)
Hernandez, A., Maisenbacher, H.J., Stoll, K.D.: Synergistische Wirkung einer Kombination von Clofibrat und β-Pyridylcarbinol im Verhältnis 20:1 bei der Behandlung primärer Hyperlipoproteinämie IIa, IIb und IV. Therapiewoche25, 36 (1975)
Wilke, H., Frahm, H.: Behandlung der Hyperlipoproteinämie Typen IIa, IIb, IV und V mit einer Clofibrat inositolnicotinat-Kombination — Ergebnisse einer Dreiphasenstudie. Münch. Med. Wschr.101, 401 (1976)
Schneider, J., Haase, W., Kaffarnik, H.: Feldstudie zur Lipidsenkung mit Etofibrat. Fortschr. Med. 785 (1976)
Samuel, P., Holtzmann, C.M., Meilman, E., Sekowski, I.: Reduction of serum cholesterol and triglyceride levels by the combined administration of neomycin and clofibrate. Circulation XLI, 109 (1970)
Montafis, C.D., Myant, N.B., Mancini, M., Oriente, P.: Cholestyramine and nicotinic acid in the treatment of familial hyperbetalipoproteinaemia in the homozygous form. Atherosclerosis14, 247 (1971)
Kellner, R., Matzkies, F., Bey, G.: Medikamentöse Kombinationstherapie der Hyperlipoproteinämie. Fortschritte Med.93, 529 (1975)
Levy, R.I. et al.: Dietary and drug treatment of primary hyperlipoproteinemia. Ann. Int. Med.77, 267 (1972)
Levy, R.I., Morganroth, J., Rifkind, B.M.: Drug therapy — treatment of hyperlipidemia. New Engl. J. Med.290, 1295 (1974)
Schettler, G.: Behandlung der Hyperlipoproteinämien. Schriftenreihe der Bundesapothekerkammer zur wiss. Fortbildung, Werbe- und Vertriebsgesellschaft Deutscher Apotheker m.b.h., Frankfurt am Main 1976
Wollenweber, J.: Medikamentöse Therapie der Hyperlipidämien. Zeitschr. f. Allgemeinmed.52, 1674 (1976)
Ströhla, H.: Erfolgskontrolle der Hyperlipoproteinämiebehandlung in einer Lipidambulanz. Inaugural-Dissertation, Heidelberg 1974
Buchwald, H.: The development of the sub-total ileal bypass operation as a therapeutic approach to hypercholesterolemia and atherosclerosis: a review. Diseases Chest51, 459 (1976)
Starzl, T.E., Chase, H.P., Putnam, C.W., Porter, K.A.: Portocaval shunt in hyperlipoproteinemia. Lancet2, 940 (1973)
Torsvik, H., Feldman, H.A., Fischer, J.E., Less, R.E.: Effects of intravenous hyperalimentation on plasmalipoproteins in severe familial hypercholesterolemia. Lancet1, 601 (1975)
Thompson, G., Lowenthal, R., Myant, N.B.: Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet1, 7918 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klose, G., Mordasini, R., Middelhoff, G. et al. Medikamentöse Behandlung primärer Hyperlipoproteinämien. Klin Wochenschr 56, 99–110 (1978). https://doi.org/10.1007/BF01478565
Issue Date:
DOI: https://doi.org/10.1007/BF01478565
Key words
- Hyperlipoproteinemia
- Atherosclerosis
- Hypolipidemic agents
- Cholestyramine
- Clofibrate
- D-thyroxine
- Nicotinic acid
- Sitosterol